Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by savannahssavvyon Aug 17, 2010 8:23pm
572 Views
Post# 17359341

RE: RE: easy

RE: RE: easyApologies for the stoopid question that follows, but I'm trying to figure out the share structure of SSS (I'm teary-eyed from all of the turmeric and piperine around here, and really can't see - or think - straight lol):

•as of 9 August 2010, Peterson owns approximately 12% of SSS (according to Stockwatch)
•as of 27 January 2009, Transition Therapeutics was no longer a 10% security holder (according to SEDI)

Did someone or some entity purchase the 10% from Transition Therapeutics sometime between January 2009 and now, or is Peterson the first to take the plunge?

Thanks in advance to anyone who might answer my query.


Bullboard Posts